News – Page 917 – Endpoints News

SIGN UP

GSK culls more respiratory drugs out of PhII as focus shifts to cancer

6 years ago

Laser-focused on colorectal cancer test, Freenome wins $160M from marquee VC pack led by RA, Polaris

6 years ago

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ ...

6 years ago

Novartis backs Harvard spinout's quest to build TCR repository in $48M round

6 years ago

Novartis, AstraZeneca vet Jonathan Symonds steers back to a top post in Big Pharma, this time at GSK

6 years ago

Intra-Cellular shares mauled as a firestorm of speculation over adcomm cancellation spreads across BioTwitter

6 years ago

FDA OKs Humira copycat from Merck, Samsung Bioepis — but they will wait 4 years to launch

6 years ago

Sharpless outlines FDA’s key priorities for advancing public health

6 years ago

Celgene restructures a big Jounce pact, zeroing in on new I/O pathway with $530M deal — and bumping ICOS

6 years ago

Proteostasis shakes up medical team; Novo funds antibiotics efforts out of Curza, Spero

6 years ago

Stay tuned: Biogen’s numbers are great — it’s their worrisome future that leaves analysts skittish

6 years ago

PACT Pharma says it's perfected the tech to select neoantigens for personalized therapy — now onto the clinic

6 years ago

Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?

6 years ago

Little Marinus sees its shares eclipsed as the Sage rival fails to compare on PPD in PhII

6 years ago

Frequency follows Astellas pact with $62M round to bankroll PhII of lead regenerative drug

6 years ago

3 years after the FDA forced Chiasma back into PhIII, they’re back with positive data — but now they have a rival

6 years ago

Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza

6 years ago

Acadia is making the best of it, but their latest PhIII Nuplazid study is a bust

6 years ago

Vertex gets NDA going for CF triple combo; Disarm woos rare disease expert Alvin Shih as CEO

6 years ago

Takeda reports second PhIII win for subcutaneous Entyvio as regulators review expanded use

6 years ago

FDA discusses RWD, RWE with industry, academia

6 years ago

Some Big Pharmas stepped up their game on data transparency — but which flunked the test?

6 years ago

Breaking the death spiral: Hal Barron talks about transforming the moribund R&D culture at GSK in a critical year for ...

6 years ago

Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks ...

6 years ago

First page Previous page 914 915 916917918 919 920 Next page Last page